Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash & Equivalents (2016 - 2025)

VYNE Therapeutics' Cash & Equivalents history spans 10 years, with the latest figure at $24.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 20.58% year-over-year to $24.0 million; the TTM value through Dec 2025 reached $24.0 million, up 20.58%, while the annual FY2025 figure was $24.0 million, 20.58% up from the prior year.
  • Cash & Equivalents reached $24.0 million in Q4 2025 per VYNE's latest filing, up from $22.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $118.5 million in Q1 2021 to a low of $47000.0 in Q3 2024.
  • Average Cash & Equivalents over 5 years is $33.9 million, with a median of $28.2 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: surged 45601.49% in 2023, then plummeted 99.7% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $605000.0 in 2021, then plummeted by 88.93% to $67000.0 in 2022, then soared by 45601.49% to $30.6 million in 2023, then plummeted by 34.92% to $19.9 million in 2024, then increased by 20.58% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Cash & Equivalents are $24.0 million (Q4 2025), $22.0 million (Q2 2025), and $28.2 million (Q1 2025).